Further processing options
First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer.
Saved in:
Journal Title: | Journal of Clinical Oncology |
---|---|
Authors and Corporations: | , , , , , , , , , |
In: | Journal of Clinical Oncology, 35, 2017, 15_suppl, p. e16562-e16562 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Society of Clinical Oncology (ASCO)
|
Subjects: |